| |
Birmingham Hip Resurfacing -
Literature Review
Survivorship
The survivorship estimates were based on the number of patients with no
revision. Survivorship analyses were provided for various cohorts and
demographic subgroups calculated according to Peto’s adjustment method
as follows (Table 15).
|
Table 15: % Survivorship Analyses (no revision) |
|
Population |
1
Year |
2
Years |
3
Years |
4
Years |
5
Years |
| X-Ray Cohort |
99.2 |
99.2 |
98.4 |
98.4 |
98.4 |
| Oswestry Cohort |
99.4 |
99.0 |
98.7 |
98.6 |
98.4 |
| X-Ray/Oswestry
Combined Cohort |
99.4 |
99.0 |
98.7 |
98.6 |
98.4
(95%Cl,
97.3-99.5%) |
| McMinn Cohort |
99.6 |
99.6 |
99.6 |
99.6 |
99.6 |
| Overall McMinn
Cohort |
99.4 |
99.1 |
98.8 |
98.7 |
98.5
(95%Cl,
97.4-99.6%) |
| |
|
|
|
|
|
| Male1 |
99.4 |
99.2 |
98.9 |
98.9 |
98.6 |
| Female1 |
99.4 |
99.0 |
98.5 |
98.2 |
98.2 |
| |
|
|
|
|
|
| Age ≤ 65 Years1 |
99.5 |
99.2 |
98.8 |
98.7 |
98.5 |
| Age > 65 Years1 |
99.0 |
99.0 |
99.0 |
99.0 |
99.0 |
| |
|
|
|
|
|
| Dx: AVN1 |
98.9 |
98.9 |
96.7 |
96.7 |
92.1
(95% Cl,
82.2-100%) |
| Dx: Dysplasia1 |
99.4 |
99.4 |
98.9 |
98.1 |
98.1 |
| Dx: OA1 |
99.5 |
99.1 |
98.8 |
98.8 |
98.8
(95%Cl,
98.3-99.4%) |
| Dx: Inflammatory1 |
98.1 |
98.1 |
98.1 |
98.1 |
98.1 |
| Dx: Other1 |
100.0 |
100.0 |
100.0 |
100.0 |
100.0 |
| |
|
|
|
|
|
| Unliateral1 |
99.4 |
99.1 |
98.8 |
98.6 |
98.4 |
| Bilateral1 |
99.6 |
99.2 |
98.8 |
98.8 |
98.8 |
| |
|
|
|
|
|
| Baseline OSHIP ≤ 632 |
99.0 |
98.7 |
98.7 |
98.7 |
98.7 |
| Baseline OSHIP > 632 |
99.8 |
99.3 |
98.7 |
98.3 |
98.3 |
| Baseline OSHIP
Missing2 |
99.5 |
99.5 |
98.8 |
98.8 |
98.3 |
| |
|
|
|
|
|
| BMI ≤ 262 |
99.7 |
99.3 |
99.0 |
98.8 |
98.8 |
| BMI > 262 |
99.1 |
98.9 |
98.7 |
98.7 |
98.3 |
| BMI Missing2 |
99.4 |
99.1 |
98.1 |
98.1 |
98.1 |
1 For the Overall
McMinn cohort (2,385 hips)
2 For the X-Ray + Oswestry cohorts (1,626 hips)
There were no statistically
significant differences in cumulative 5-year survival (revision-free)
probabilities among three study cohorts. The following Figure 1
summarizes these cumulative survival probabilities (all hips):
Figure 1. Cumulative %
Revision-Free, BHR

Due to small number of
revisions (total 25, < 5-year follow-up) from large numbers in three
study cohorts (total of 2,385 hips), there were no statistically
significant differences for all pairwise comparisons in 5-year survival
(revision-free) probabilities among three cohorts, either by log-rank
test, Wilcoxon test, or Cox proportional hazard (PH) regression
analysis. Both the Cox PH regression model and the log-rank test require
that the two survival probability curves be parallel or nearly parallel
(no significant cohort by time crossover).
The above three statistical
significance tests were also applied to several clinically important
patient covariates,
which include age (<65, >65), gender (M, F), reason for resurfacing (AVN,
OA, IA, dysplasia, and others; reference group = OA), baseline OSHIP
score (yes, no), hips (unilateral, bilateral). The only marginally
statistically significant difference in 5-year survival probability was
between the patients with Osteoarthritis (98.8%) and Avascular Necrosis
(92.1%) as their primary diagnostic indication. The p-values to compare
these two % revision-free curves for OA versus AVN comparison are
p=0.0415 (Log-rank) and p=0.2282 (Wilcoxon).
Due to non-parallelism of
the Oswestry and X-Ray survival curves, careful clinical interpretation
is needed. Both log-rank and Wilcoxon test that the two revision-free
curves are equal, and the Cox PH model tests that the ratio of the two
hazards (probability of revision) is unity. The log-rank test assigns
equal weight to all follow-up times and the Wilcoxon test assigns more
weight to the earlier follow-up times where more patients are at risk of
revision. The log-rank test has optimum statistical power if the
parallelism assumption for the two revision-free curves is valid. The
Cox PH model is not appropriate here due to obvious non-parallelism of
the two curves in Figure 1. The percentages of revisions are 3.1% (3/97)
for AVN, 1.1% for dysplasia (4/377), 0.95% (17/1789) for OA, 1.7% (1/57)
for Inflammatory arthritis (IA), and 0% for others (0/65), with a
combined 1% (25/2,385) revisions over all diagnostic groups, during
5-year follow-up.
Radiographic Data
The clinical data used to support this series contained the results of
an independent radiographic review of the X-Ray Cohort, the first 124
procedures performed in the series from July 1997 through December 1997.
Radiographs were taken on
108 of the 118 procedures expected at 5 years postoperatively (91.5%).
Six (6) procedures were not expected at 5 years postoperatively because
one patient with bilateral hip implants died from a motor neuron disease
unrelated to the BHR procedure; and 4 of the 124 BHR procedures (3.2%)
have undergone revision: 3 cases were revised for infection, and 1 case
required revision because of a femoral neck fracture. Therefore, 118
procedures (124 hips - 2 hips due to death - 4 revisions = 118
procedures) were eligible for 5 year radiographic evaluation of the BHR.
Ten other cases were missing due to lost to follow-up or incomplete film
records. Therefore, one hundred and eight (108) of the 118 hips
surviving to 5 years had 5 year radiographs available for independent
review (91.5%). (Note: An additional bilateral patient died 7 years
post-op due to stroke but had 5 year x-rays taken).
Baseline films for the
purposes of comparisons were made in each of the 108 cases in the
postoperative time
period (usually within 3 months, but 8 of the 108 procedures had
baseline evaluations performed at time points
ranging from 110-860 days).
Radiographic Study: 5-Year Radiographic Assessments
The radiographs were assessed for radiolucencies, bone resorption,
heterotopic bone, acetabular angle, medial-lateral migration, and other
observations to determine whether a revision surgery was necessary.
Femoral radiolucencies:
Radiolucencies were graded 0-9 (Amstutz scale). There were femoral
radiolucencies found in 4 cases (4.1%) - 1 each with grade 9
(migration), grade 5 (zone 2-3), grade 2 (zone 1) and grade 1 (zone 2).
The patient with a grade 9 femoral radiolucency was classified as a
radiographic failure.
Acetabular radiolucency:
Radiolucencies were graded 0-9 (DeLee and Charnley scale). There were 2
hips with acetabular radiolucencies, both with grade 8 (zones I-III,
complete) findings. One hip had preoperative acetabular cysts that
progressed over time, and the other had a preoperative dysplastic
acetabulum and developed protrusio. Both were classified as radiographic
failures. Three patients had insignificant radiolucencies (grade 1 in
two hips and grade 2 in one hip).
Heterotopic bone:
There were 21 hips that had Brooker I and 5 hips with Brooker II
heterotopic ossification (HO). Only 2 hips had “clinically significant
HO,” (i.e., Brooker III or IV). Both had Brooker III HO. Thus, 28 of the
108 procedures evaluated (28.9%) had any heterotopic bone at 5 years and
2.1% had significant HO. None of the cases with heterotopic bone were
determined to require a revision.
Acetabular angle:
There was only 1 case that had a change in the acetabular angle >5̃.
This patient also had the grade 8 acetabular radiolucency (see above).
No cases had a change in acetabular angle that was determined to be an
indication for a revision.
Medial / Lateral
Migration: There were no procedures with a change in medial/lateral
acetabular cup position, and no cases with a change in acetabular
position that was determined to be an indication for a revision.
Additional observations: Bone resorption at the femoral neck was found
in 3 cases. In no case was the resorption associated with any other
notable radiographic findings. Bone cysts were found in 2 patients: one,
described above, and the other had 3cm cysts associated with a grade 1
acetabular radiolucency. No other significant signs were noted.
Three (3) of the 108 (2.8%)
patients for whom radiographs were available were radiographic failures
at 5 years (Table 16).
|
Table 16: Radiographic Findings - Number of procedures (%) |
|
Findings |
Number (%) |
| Femoral
radiolucencies |
|
| Failure: Grade 9 |
1
(0.9%) |
| Other: Grade 1 |
1
(0.9%) |
| Other: Grade 2 |
1
(0.9%) |
| Other:
Grade 5 |
1 (0.9%) |
| Acetabular
radiolucencies |
|
| Failure: Grade 81 |
2
(1.8%) |
| Other: Grade 1 |
2
(1.8%) |
| Other: Grade 2 |
1
(0.9%) |
| Change in
orientation/migration |
|
| 5̃ change in
orientation1 |
1
(0.9%) |
| Heterotopic
ossification |
|
| Brooker IV |
0
(0.0%) |
| Brooker III |
2
(1.8%) |
| Brooker II |
5
(4.6) |
| Brooker I |
21
(19.4%) |
| Other |
|
| Bone resorption,
femoral neck |
3
(2.8%) |
| Femoral of
acetabular cyst |
2
(1.8%) |
1 Occurred in the
same patient.
Radiographic Study: Comparison to Literature Reference
The radiographic results were compared with the literature reference
group (Table 17).
|
Table 17: Radiographic Findings - X-Ray Cohort vs. Literature
Reference |
|
Radiographic Finding |
Overall
McMinn
Cohort |
Garino
Reference* |
D'Antonio
Reference |
ABC with
porous
(n=162)** |
ABC with HA
(n=169)* |
Reference Control
M/PE (n=149)** |
| Femoral RL Zone 1 |
1
(0.9%) |
- |
4
(2.5%) |
4
(2.4%) |
6
(4.0%) |
| Femoral RL Zone 2 |
1
(0.9%) |
- |
|
|
|
| Femoral RL 2 & 3 |
1
(0.9%) |
|
|
|
|
| Femoral RL Zone 7 |
0 |
- |
2
(1.2%) |
1
(0.6%) |
0 |
| Stem Subsidence |
0 |
- |
0 |
11
(0.6%) |
0 |
| Unstable Stem |
1
(0.9%) |
- |
0 |
11
(0.6%) |
0 |
| Cup RL Zone I |
2
(1.8%) |
- |
10
(6.2%) |
1
(0.6%) |
10
(6.7%) |
| Cup RL Zone II |
1
(0.1%) |
- |
3
(1.9%) |
0 |
7
(4.7%) |
| Cup RL Zone III |
0 |
- |
25
(15.4%) |
0 |
35
(23.5%) |
| Cup RL all 3 zones |
2
(1.8%) |
- |
0 |
0 |
0 |
| Cup Migration |
1
(0.9%) |
- |
0 |
0 |
12
(0.7%) |
| Cup Unstable |
1
(0.9%) |
- |
1
(0.6%) |
0 |
12
(0.7%) |
* No radiographic data.
** Revision rates are based on a minimum of 2-year follow-up and
available x-rays.
1 Same femoral component.
2 Same acetabular component.
Pain and Function - Oswestry Modified Harris Hip (OSHIP)
Score—Unilateral Procedures Only
FDA believes that it is difficult to assess the pain and function of
each hip separately in patients with bilateral hip involvement using the
Harris Hip Score or the Oswestry-modified Harris Hip Score (OSHIP),
because it is difficult to distinguish the contributions of each hip on
functional assessments such as walking or support, walking distance,
stair-climbing, sitting, and transportation. Therefore, FDA believes
only the unilateral patients should be used in an analysis of pain and
function for the purposes of evaluating safety and effectiveness.
The mean OSHIP Scores
(unilateral procedures only) improved from a baseline mean of 60.1 to
94.8 at 5 years. For the group of patients who had high baseline OSHIP
scores (>80), the mean OSHIP scores improved from 84.5 to 99.3. The
group of patients who had low baseline OSHIP scores (<80), the mean
OSHIP scores also improved from 59.4 to 95.6. At postoperative years 2,
3, 4 and 5, the percentage of cases with good or excellent OSHIP scores
was 96.9%, 95.8%, 95.2%, and 92.8%, respectively (Table 18)
Table 18: Oswestry-Modified Harris Hip Score (OSHIP)
X-Ray/Oswestry Combined Cohort -
Unilateral only |
| |
Baseline |
1
Year |
2
Years |
3
Years |
4
Years |
5
Years |
| Expected |
1111 |
1103 |
1100 |
927 |
687 |
395 |
| OSHIP assessments |
892 |
835 |
842 |
818 |
607 |
360 |
| OSHIP
mean |
60.1 |
96.6 |
96.8 |
96.2 |
95.9 |
94.8 |
| SD* |
13.1 |
6.75 |
7.3 |
7.4 |
8.0 |
9.7 |
| SE** |
0.44 |
0.23 |
0.25 |
0.26 |
0.32 |
0.51 |
| 95% CI |
(59,
61) |
(96,
97) |
(96.3, 97.3) |
(95.7, 96.9) |
(95.2, 96.6) |
(93.8. 95.8) |
| |
|
|
|
|
|
|
| AVN OSHIP mean |
49.4 |
91.3 |
93.6 |
96.2 |
94.3 |
97.4 |
| N, AVN |
43 |
35 |
38 |
32 |
23 |
14 |
| Dysplasia OSHIP mean |
57.7 |
96.2 |
96.7 |
95.2 |
94.7 |
90.6 |
| N, Dysplasia |
131 |
123 |
117 |
117 |
81 |
44 |
| OA OSHIP mean |
61.5 |
97.0 |
97.0 |
96.5 |
96.2 |
95.3 |
| N, OA |
678 |
642 |
652 |
632 |
484 |
287 |
| IA OSHIP mean |
48.5 |
95.5 |
94.9 |
93.2 |
91.6 |
89.3 |
| N, IA |
15 |
11 |
11 |
15 |
10 |
8 |
| Other OSHIP mean |
62.9 |
96.5 |
98.3 |
96.6 |
98.8 |
98.4 |
| N, Other |
25 |
24 |
24 |
22 |
9 |
7 |
| |
|
|
|
|
|
|
OSHIP mean for
procedures with
baseline ≥80 |
84.5 |
96.1 |
97.8 |
97.3 |
99.6 |
99.3 |
| N, for baseline
≥80 |
25 |
22 |
22 |
18 |
8 |
3 |
OSHIP mean for
procedures with
baseline <80 |
59.4 |
96.9 |
96.9 |
96.6 |
96.4 |
95.6 |
| N, for baseline<80 |
867 |
693 |
686 |
635 |
440 |
240 |
| |
|
|
|
|
|
|
OSHIP mean for
procedures with
baseline OSHIP |
60.1 |
96.9 |
96.9 |
96.9 |
96.5 |
95.6 |
| N, with baseline
OSHIP |
892 |
715 |
708 |
653 |
448 |
243 |
OSHIP mean for
procedures without
baseline OSHIP |
- |
94.8 |
96.2 |
94.8 |
94.1 |
92.9 |
| N, without baseline
OSHIP |
- |
120 |
134 |
165 |
159 |
117 |
| |
|
|
|
|
|
|
| Improved
≥10% |
- |
703
(84.2) |
697
(82.8) |
645
(78.9) |
445
(73.3) |
239
(66.4) |
| Maintained (%) |
- |
130
(15.6) |
142
(16.9) |
173
(21.1) |
161
(26.5) |
121
(33.6 |
| Deteriorated ≥10% |
- |
2
(0.2) |
3
(0.4) |
0 |
1
(0.2) |
0 |
| |
|
|
|
|
|
|
| OSHIP Excel ≥90 (%) |
2
(0.2) |
757
(92.0) |
775
(92.0) |
722
(88.3) |
529
(87.1) |
307
(85.3) |
| OSHIP Good 80-89 (%) |
23
(2.6) |
56
(6.7) |
41
(4.9) |
61
(7.5) |
49
(8.1) |
27
(7.5) |
| OSHIP Fair 70-79 (%) |
175
(19.6) |
12
(1.4) |
14
(1.7) |
20
(2.4) |
16
(2.6) |
12
(3.3) |
| OSHIP Poor 60-69 (%) |
349
(39.1) |
3
(0.4) |
5
(0.6) |
9
(1.1) |
8
(1.3) |
8
(2.2) |
| OSHIP V Poor <60 (%) |
343
(38.5) |
7
(0.8) |
7
(0.8) |
6
(0.7) |
5
(0.8) |
6
(1.7) |
* SD = Standard deviation;
**SE = Standard error of sample mean = SD/Vn ; CI = confidence interval
of true OSHIP
mean.
For the data in the table
above regarding the number of procedures who improved >10 pts.,
maintained, or deteriorated >10 pts., that those patients with no
baseline scores were counted as “maintained.” The table below contains
an analysis of the number of procedures who improved >10 pts.,
maintained, or deteriorated >10 pts., when the patients without baseline
scores are removed from this analysis and just counted as missing (Table
19).
|
Table 19: OSHIP Improvement - Oswestry & X-Ray Cohorts |
| |
Change |
1
Year |
2
Years |
3
years |
4
Years |
5+
Years |
| Unilateral |
Improved ≥10 |
703
(98.3) |
697
(98.3) |
645
(98.4) |
445
(99.3) |
239
(98.4) |
| |
Same <10 |
10
(1.4) |
8
(1.1) |
8
(1.2) |
2
(10.4) |
4
(1.6) |
| |
Worse ≥10 |
2
(0.3) |
3
(0.4) |
0
(0.0) |
1
(0.2) |
0
(0.0) |
| |
N |
715 |
708 |
653 |
448 |
243 |
| |
Missing |
388 |
392 |
274 |
239 |
152 |
Pain and Function - Comparison to Literature References
In the literature references, the authors used Harris Hip Score, not
OSHIP, to collect pain and function effectiveness data. D’Antonio et al.
reported Harris Hip Scores at 2 - 4 year follow up (mean 3 year) for the
ceramic-on-ceramic hip procedures as follows:
• ABC System 1 (porous):
95.4 mean score (n=166)
• ABC System 2 (HA): 96.6 mean score (n= 172)
Garino reported an average
increase in Harris Hip Score from 44 pre-operatively to a mean of 97 at
follow up.
Patient Satisfaction
The patient satisfaction question is not a standard component of the
OSHIP assessment but was an additional question asked for this study in
the annual, patient-completed, mail-in questionnaire. At 5 years, 99.5%
of the procedures in the X-Ray/Oswestry combined cohort were pleased or
very pleased with the operation. At 5 years, 99.2% of the unilateral
procedures from the X-Ray/Oswestry combined cohort were pleased or very
pleased with the operation (Table 20).
Table 20: Patient Satisfaction
X-Ray / Oswestry Combined Cohort |
| |
X-Ray / Oswestry
Combined Cohort N = 1626 |
| |
Base |
1
Year |
2
Years |
3
Years |
4
Years |
5+
Years |
| N |
1626 |
1616 |
1607 |
1349 |
1007 |
601 |
| Pleased |
- |
75
(6.1%) |
62
(5.0%) |
80
(6.7%) |
50
(5.6%) |
31
(5.7%) |
| Very Pleased |
- |
1109
(89.6%) |
1177
(94.7%) |
1100
(92.7%) |
839
(94.1%) |
512
(93.8%) |
| |
|
|
|
|
|
|
| # All unilateral |
1111 |
1103 |
1100 |
927 |
687 |
395 |
| Assessments |
892 |
835 |
842 |
818 |
607 |
360 |
| Please/ Very Pleased
(VP) |
- |
800
|
839
|
813
|
604
|
357
|
| N, AVN |
43 |
35 |
38 |
32 |
23 |
14 |
| AVN Pleased/ VP |
- |
35
(100.0%) |
38
(100.0%) |
32
(100.0%) |
23
(100.0%) |
14
(100.0%) |
| N, Dysplasia |
131 |
123 |
117 |
117 |
81 |
44 |
| Dysplasia Pleased/
VP |
- |
119
(96.8%) |
117
(100.0%) |
115
(98.3%) |
80
(98.7%) |
43
(97.7%) |
| N, OA |
678 |
642 |
652 |
632 |
484 |
287 |
| OA Pleased/ VP |
- |
613
(95.5%) |
649
(99.6%) |
630
(99.7%) |
482
(99.6%) |
285
(99.3%) |
| N, IA |
15 |
11 |
11 |
15 |
10 |
8 |
| IA Pleased/ VP |
- |
11
(100.0%) |
11
(100.0%) |
15
(100.0%) |
10
(100.0%) |
8
(100.0%) |
| N, Other |
25 |
24 |
24 |
22 |
9 |
7 |
| Other Pleased/VP |
- |
22
(91.7%) |
24
(100.0%) |
21
(95.5%) |
9
(100.0%) |
7
(100.0%) |
Return to BHR Literature Review
Back to Patient Education - Hip
2/4/2007
OUR
SERVICES | PATIENT EDUCATION
| ABOUT DR. ROGERSON
CLINIC INFORMATION |
OUR TEAM | CURRICULUM VITAE

|